The discovery of the PD-1 receptor and its ligand PD-L1 revolutionized our understanding of immune regulation and, together with that of CTLA-4, allowed the development of immune checkpoint blockade, now a cornerstone of cancer therapy. This evidence concerns the gene CTLA4 and cancer.